Showing results (1351-1360 of 1,377) with videos related to
Sort By:
Pageof 138
Journal of Viral Hepatitis|July 2, 2013
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirinM P Manns, P J Pockros, G Norkrans, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 15, 2013
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trialsMichael P Manns, Jonathan McCone, Mitchell N Davis, et al.Journal of the Canadian Association of Gastroenterology|September 7, 2023
The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBDStephanie Coward, Eric I Benchimol, M Ellen Kuenzig, et al.Antiviral Therapy|February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trialRobert A Ogert, John A Howe, John M Vierling, et al.Nature Biotechnology|March 1, 2003
A systematic approach to modeling, capturing, and disseminating proteomics experimental dataChris F Taylor, Norman W Paton, Kevin L Garwood, et al.Hepatology (Baltimore, Md.)|May 10, 2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM studyQuentin M Anstee, Kathryn J Lucas, Sven Francque, et al.Nature Medicine|February 16, 2023
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trialArun J Sanyal, Patricia Lopez, Eric J Lawitz, et al.Journal of the American College of Cardiology|October 20, 2022
Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year OutcomesJacqueline Saw, Andrew Starovoytov, Eve Aymong, et al.The New England Journal of Medicine|February 18, 2016
Pioglitazone after Ischemic Stroke or Transient Ischemic AttackWalter N Kernan, Catherine M Viscoli, Karen L Furie, et al.Nature|March 27, 2012
IFITM3 restricts the morbidity and mortality associated with influenzaAaron R Everitt, Simon Clare, Thomas Pertel, et al.Pageof 138